{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Intravitreal+Injection",
    "query": {
      "condition": "Intravitreal Injection"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 256,
    "total_pages": 26,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Intravitreal+Injection&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T21:12:16.454Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05158296",
      "title": "Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Retinitis Pigmentosa",
        "Usher Syndrome Type 2",
        "Deaf Blind",
        "Retinal Disease",
        "Eye Diseases",
        "Eye Diseases, Hereditary",
        "Eye Disorders Congenital",
        "Vision Disorders"
      ],
      "interventions": [
        {
          "name": "Ultevursen",
          "type": "DRUG"
        },
        {
          "name": "Sham-procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Laboratoires Thea",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2021-12-08",
      "completion_date": "2022-10-12",
      "has_results": true,
      "last_update_posted_date": "2024-07-12",
      "last_synced_at": "2026-07-22T21:12:16.454Z",
      "location_count": 10,
      "location_summary": "San Diego, California • San Francisco, California • Miami, Florida + 7 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05158296"
    },
    {
      "nct_id": "NCT01722656",
      "title": "Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Submacular Vascularized Pigment Epithelial Detachments"
      ],
      "interventions": [
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southern California Desert Retina Consultants, MC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2012-11",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2016-01-22",
      "last_synced_at": "2026-07-22T21:12:16.454Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Palm Desert, California • Rapid City, South Dakota",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Rapid City",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01722656"
    },
    {
      "nct_id": "NCT04340505",
      "title": "Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Uveitis"
      ],
      "interventions": [
        {
          "name": "Fluocinolone Acetonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2019-08-08",
      "completion_date": "2026-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-07-22T21:12:16.454Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04340505"
    },
    {
      "nct_id": "NCT05417126",
      "title": "Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stargardt Disease"
      ],
      "interventions": [
        {
          "name": "Gene Therapy-vMCO-010",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Nanoscope Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2022-07-05",
      "completion_date": "2023-09-28",
      "has_results": false,
      "last_update_posted_date": "2023-11-09",
      "last_synced_at": "2026-07-22T21:12:16.454Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • McAllen, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "McAllen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05417126"
    },
    {
      "nct_id": "NCT04144985",
      "title": "Comfort Comparison of Intravitreal Injection Eyelid Retraction Techniques",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Intravitreal Injection",
        "Pain"
      ],
      "interventions": [
        {
          "name": "Visual analog scale (VAS) of pain to evaluate the discomfort participants experience.",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "New York City Health and Hospitals Corporation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2017-10-01",
      "completion_date": "2018-03-31",
      "has_results": false,
      "last_update_posted_date": "2019-10-30",
      "last_synced_at": "2026-07-22T21:12:16.454Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04144985"
    },
    {
      "nct_id": "NCT03666923",
      "title": "A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Diabetic Retinopathy",
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "THR-687 dose level 1",
          "type": "DRUG"
        },
        {
          "name": "THR-687 dose level 2",
          "type": "DRUG"
        },
        {
          "name": "THR-687 dose level 3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ThromboGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-09-17",
      "completion_date": "2019-11-20",
      "has_results": false,
      "last_update_posted_date": "2020-01-22",
      "last_synced_at": "2026-07-22T21:12:16.454Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        },
        {
          "city": "West Columbia",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03666923"
    },
    {
      "nct_id": "NCT07064759",
      "title": "Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration (nAMD)"
      ],
      "interventions": [
        {
          "name": "4D-150 IVT (3E10 vg/eye)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "4D Molecular Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 480,
      "start_date": "2025-07-22",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-07-22T21:12:16.454Z",
      "location_count": 54,
      "location_summary": "Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07064759"
    },
    {
      "nct_id": "NCT02288559",
      "title": "A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "Sham",
          "type": "OTHER"
        },
        {
          "name": "Lampalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2015-03-30",
      "completion_date": "2017-06-02",
      "has_results": true,
      "last_update_posted_date": "2019-09-25",
      "last_synced_at": "2026-07-22T21:12:16.454Z",
      "location_count": 36,
      "location_summary": "Mesa, Arizona • Tucson, Arizona • Springdale, Arkansas + 33 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02288559"
    },
    {
      "nct_id": "NCT01578720",
      "title": "Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Choroidal Neovascularization",
        "Presumed Ocular Histoplasmosis"
      ],
      "interventions": [
        {
          "name": "EYLEA (Aflibercept) intravitreal injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Retina Research Institute, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2012-06",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2018-08-29",
      "last_synced_at": "2026-07-22T21:12:16.454Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01578720"
    },
    {
      "nct_id": "NCT02555306",
      "title": "A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "0.5 mg of DE-122",
          "type": "DRUG"
        },
        {
          "name": "1.0 mg of DE-122",
          "type": "DRUG"
        },
        {
          "name": "2.0 mg of DE-122",
          "type": "DRUG"
        },
        {
          "name": "4.0 mg of DE-122",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2015-09-16",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2020-01-14",
      "last_synced_at": "2026-07-22T21:12:16.454Z",
      "location_count": 5,
      "location_summary": "Mountain View, California • Walnut Creek, California • Jackson, Michigan + 2 more",
      "locations": [
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Jackson",
          "state": "Michigan"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "McAllen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02555306"
    }
  ]
}